Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Baker Julian
Relationship:  
City:   New York
State:   NY
   
Insider Summary:
  
   
Companies Owned :   33    
Direct Shares   1,028,565    

Indirect Shares

   243,774,473      
Direct Value   $73,841,312    

Indirect Value

   $16,621,918,985      
Total Shares   244,803,038      
Total Value   $16,695,760,297      


Incyte Corp $32,141,876 Neurogene $16,634 Acadia Pharmaceuticals Inc $3,141,833 Aceragen, Inc $16,666 Mirati Therapeutics, Inc. $16,084 Beigene Ltd $3,488,073 Seagen Inc $10,649,448 Alexion Pharmaceuticals Inc $24,083,248 Kiniksa Pharmaceuticals, Ltd. $287,451 Incyte Corp $32,141,876 Neurogene $16,634 Acadia Pharmaceuticals Inc $3,141,833 Aceragen, Inc $16,666 Mirati Therapeutics, Inc. $16,084 Beigene Ltd $3,488,073 Seagen Inc $10,649,448 Alexion Pharmaceuticals Inc $24,083,248 Kiniksa Pharmaceuticals, Ltd. $287,451
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    46   
    7    

     Stock price went up :
    23   
    7    
     Stock price went down :
    23   
    0    
   
     Gain/Loss Ratio :
   0.0   
   7.0   
     Percentage Gain/Loss :
   11.8%
 80.1%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Synageva BioPharma Corp GEVA 10% Owner 2003-09-26 0 2011-11-02 144,082    Premium*  
            Innoviva Inc INVA Director 2005-12-13 0 2004-10-04 33,839    Premium*  
            Ardea Biosciences Inc RDEA Director, 10% Owner 2004-10-13 0 2011-06-30 4,045,398    Premium*  
            Incyte Corp INCY 2024-05-07 559,963 2024-05-07 33,496,391    Premium*  
            Genomic Health Inc GHDX Director, 10% Owner 2019-08-29 0 2019-08-29 9,262,659    Premium*  
            Allos Therapeutics Inc ALTH 10% Owner 2009-01-23 0 2009-01-23 2,258    Premium*  
            Viropharma Inc VPHM 10% Owner 0 2011-12-14 9,840,469    Premium*  
            Heron Therapeutics Inc HRTX 10% Owner 0 2009-10-19 5,264,782    Premium*  
            Diadexus Inc DDXS 10% Owner 0 2012-01-27 0    Premium*  
            Pharmacyclics Inc PCYC 10% Owner 2011-08-22 0 2012-02-10 557,211    Premium*  
            XOMA Corporation XOMA Former 10% owner 0 2015-07-22 90,538    Premium*  
            Ocera Therapeutics Inc OCRX 10% Owner 2012-03-12 0 2012-03-14 3,540,015    Premium*  
            Neurogene NGNE Director 2020-07-07 4,520 2020-07-07 3,501,691    Premium*  
            Acadia Pharmaceuticals Inc ACAD Director, 10% Owner 2021-06-22 205,752 2021-06-22 38,452,877    Premium*  
            Invitae Corp NVTA 10% Owner 2018-03-28 0 2018-03-28 7,553,553    Premium*  
            Aceragen, Inc ACGN 10% Owner 2019-07-01 43,858 2019-07-01 4,290,995    Premium*  
            Rhythm Pharmaceuticals, Inc. RYTM Former 10% owner 2017-10-05 0 2017-10-05 1,878,242    Premium*  
            Mirati Therapeutics, Inc. MRTX 10% Owner 2017-11-08 274 2017-11-08 35,999    Premium*  
            Bellicum Pharmaceuticals, Inc BLCM 10% Owner 2018-01-17 0 2018-01-19 58,131    Premium*  
            Beigene Ltd BGNE Director, 10% Owner 2021-06-16 20,838 2021-06-16 11,703,086    Premium*  
            Seagen Inc SGEN Director, 10% Owner 2021-05-14 46,557 2021-05-14 43,309,073    Premium*  
            Alexion Pharmaceuticals Inc ALXN Director 2020-05-14 131,963 2020-05-14 7,940,623    Premium*  
            Kiniksa Pharmaceuticals, Ltd. KNSA Director, 10% Owner 2019-06-06 14,840 2019-06-06 2,700,597    Premium*  
            Kodiak Sciences Inc. KOD Director, 10% Owner 2018-10-09 0 2021-09-30 13,526,726    Premium*  
            Atreca Inc BCEL 10% Owner 2019-06-24 0 2019-06-24 3,223,030    Premium*  
            Igm Biosciences, Inc. IGMS Director, 10% Owner 2019-09-20 0 2021-01-27 2,895,306    Premium*  
            Prelude Therapeutics Inc PRLD Director, 10% Owner 0 2021-01-27 9,252,951    Premium*  
            DBV Technologies SA DBVT Director, 10% Owner 0 2021-01-01 4,286,038    Premium*  
            Talis Biomedical Corp TLIS Director, 10% Owner 0 2021-02-17 7,003,766    Premium*  
            Aeglea Biotherapeutics, Inc. AGLE Director 0 2021-02-23 3,410,106    Premium*  
            Tscan Therapeutics, Inc. TCRX Director 2021-07-20 0 2021-07-20 1,320,302    Premium*  
            Entrada Therapeutics, Inc. TRDA 10% Owner 0 2021-12-14 4,704,419    Premium*  
            Bicycle Therapeutics Ltd BCYC 0 2024-04-18 6,449,320    Premium*  
* Premium Members only  

Records found :    496         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 15 of 20
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
NGNE Neurogene 10% Owner   –       –       •   2016-01-25 4 B $10.98 $121,576 I/I 10,945 6,432,847 1.5 -
BCYC Bicycle Therapeutics Ltd   –       •       •   2024-04-18 4 A $0.00 $0 I/I 24,000 6,449,320 0 -
NGNE Neurogene 10% Owner   –       –       •   2016-01-26 4 B $10.80 $839,524 I/I 77,639 6,502,773 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-08-22 3 IO $0.00 $0 I/I 0 6,526,526 -
NGNE Neurogene 10% Owner   –       –       •   2016-03-15 4 B $7.88 $877,066 I/I 109,912 6,601,891 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-08-22 4 B $9.93 $2,861,270 I/I 287,264 6,813,790 1.5 -
NGNE Neurogene 10% Owner   –       –       •   2016-03-16 4 B $7.70 $2,893,570 I/I 361,755 6,928,119 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-21 4 B $12.01 $846,886 I/I 70,173 6,965,853 1.5 -
TLIS Talis Biomedical Corp Director   –       •       •   2021-02-17 4 B $16.00 $100,000,000 I/I 6,250,000 7,003,176 2.25 -
BCYC Bicycle Therapeutics Ltd   –       •       •   2024-04-18 3 IO $0.00 $0 I/I 0 7,017,176 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-22 4 B $12.51 $1,011,570 I/I 79,131 7,044,984 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-23 4 B $12.76 $1,189,165 I/I 93,194 7,138,178 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-28 4 B $13.32 $2,001,154 I/I 150,007 7,288,185 1.5 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2019-05-30 4 S $120.12 $6,949,754 I/I (57,449) 7,382,978 0 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2019-05-29 4 S $121.37 $14,548,851 I/I (119,062) 7,434,266 0 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-29 4 B $14.12 $2,300,343 I/I 162,271 7,450,456 1.5 -
NVTA Invitae Corp 10% Owner   –       –       •   2018-03-28 4 B $4.50 $5,000,000 I/I 1,111,111 7,480,182 1.5 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-11-30 4 B $14.92 $969,966 I/I 65,002 7,515,458 1.5 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2019-05-28 4 S $125.05 $15,624,859 I/I (123,489) 7,540,560 0 -
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2011-12-02 4 B $15.39 $1,359,615 I/I 88,197 7,603,655 1.5 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2020-03-16 4 B $75.66 $20,894,753 I/I 265,298 7,626,298 2.1 %
PCYC Pharmacyclics Inc 10% Owner   –       –       •   2012-01-19 4 B $15.81 $559,459 I/I 34,857 7,638,512 1.5 -
GHDX Genomic Health Inc Director   –       •       •   2019-07-01 4 A $58.86 $149,740 I/I 2,544 7,641,672 0 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2018-05-09 4 A $0.00 $0 I/I 4,348 7,648,080 0 -
ALXN Alexion Pharmaceuticals I... Director   –       •      –    2019-05-15 4 A $0.00 $0 I/I 5,452 7,650,806 0 -
  496  Records found
  1   2   3   4   5   6   7   8   9   10   11   12   13   14   15  16   17   18   19   20      
  Page 15 of 20  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us